Leerink Partners Initiates Coverage of Collegium Pharmaceutical with Outperform
Fintel reports that on September 9, 2026, Leerink Partners initiated coverage of Collegium Pharmaceutical (NASDAQGS:COLL) with a Outperform recommendation.
Prior to the rating action, the company's stock closed at $23.37 on September 8, 2026, which is also the latest close as of that date. The stock has experienced a one-week price change of -2.62% from a baseline close of $24.00 on September 1, 2026, and a one-month price change of -20.70% from a baseline close of $29.47 on August 7, 2026.
In its latest earnings report on August 6, 2026, Collegium Pharmaceutical posted an actual EPS of 1.92, compared to an estimated EPS of 1.7495, representing an EPS surprise of +9.75%. The actual revenue was $199,878,000,000,000.00, while the estimated revenue was $205,230,120,000,000.00.
As of August 28, 2026, the current consensus target mean for the stock was $52.02, with a median target of $50.49. This mean target represents an implied change of +122.59%. This is a revision of -6.13% from the prior consensus target mean of $55.42 recorded on August 4, 2026.
The aggregate analyst recommendations as of September 1, 2026, show a total of 12 recommendations, consisting of 3 strong buy, 7 buy, 2 hold, 0 sell, and 0 strong sell ratings. This results in 83.3% positive, 16.7% hold, and 0.0% negative recommendations. These figures remain unchanged from the prior recommendation period as of August 1, 2026, which also had 12 total recommendations with the same distribution of 3 strong buy, 7 buy, 2 hold, 0 sell, and 0 strong sell ratings.
In other recent analyst activity, Barclays maintained its rating of Overweight for Collegium Pharmaceutical on August 19, 2026, keeping the rating at Overweight.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 9, 2026 | Leerink Partners | Outperform | initiated coverage | |
| August 19, 2026 | Barclays | Overweight | Overweight | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.